keyword
MENU ▼
Read by QxMD icon Read
search

Bevacizumab glioblastoma

keyword
https://www.readbyqxmd.com/read/27903792/clinical-effectiveness-of-bevacizumab-in-patients-with-recurrent-brain-tumours-a-population-based-evaluation
#1
REVIEW
Mário L de Lemos, Adeline Markarian, Esther Chan, Kimberly Schaff, Susan Walisser
BACKGROUND: Bevacizumab is an antiangiogenic agent active in patients with recurrent malignant gliomas. However, evidence for its clinical efficacy is relatively limited so that bevacizumab is approved for this indication in Canada and the United States, but not in the European Union. We reviewed the effectiveness of bevacizumab in patients with recurrent brain tumour using a large population database. METHODS: This was a retrospective, multicentre, study conducted at the BC Cancer Agency, a public cancer care organisation for the residents of the Canadian province of British Columbia...
November 30, 2016: Journal of Oncology Pharmacy Practice
https://www.readbyqxmd.com/read/27896520/early-perfusion-mri-predicts-survival-outcome-in-patients-with-recurrent-glioblastoma-treated-with-bevacizumab-and-carboplatin
#2
Iwan E Bennett, Kathryn M Field, Christopher M Hovens, Bradford A Moffat, Mark A Rosenthal, Katharine Drummond, Andrew H Kaye, Andrew P Morokoff
Bevacizumab, an anti-angiogenic agent, is FDA-approved for use in patients with recurrent glioblastoma multiforme (rGBM). The radiologic evaluation of tumor response to bevacizumab is complex and there is no validated method of monitoring tumor vascularity during therapy. We evaluated perfusion-weighted MR imaging (PWI) in our cohort of patients enrolled in the CABARET trial, which examined the effectiveness of bevacizumab with or without carboplatin in patients with rGBM. Pre-treatment and early follow-up (4- and 8-week) PWI were used to calculate relative cerebral blood volume (rCBV) histogram statistics of the contrast-enhancing and FLAIR hyperintense tumor volumes...
November 28, 2016: Journal of Neuro-oncology
https://www.readbyqxmd.com/read/27849336/durability-of-single-dose-intra-arterial-bevacizumab-after-blood-brain-barrier-disruption-for-recurrent-glioblastoma
#3
Shamik Chakraborty, Christopher G Filippi, Jan-Karl Burkhardt, Sherese Fralin, Ashley Ray, Tamika Wong, Rafael Ortiz, David J Langer, John A Boockvar
BACKGROUND: Bevacizumab (BV) has been used to treat recurrent glioblastoma with a progression free survival of approximately 3-3.5 months. Typically, it is administered intravenously every 2-3 weeks at dosages ranging from 5-15 mg/kg. Serious side effects include GI tract perforations, hematologic disorders, intracranial hemorrhage, and malignant hypertension. We hypothesized that selective intracranial intra-arterial infusion (SIACI) of BV following blood/brain barrier disruption (BBBD) with mannitol may allow for reduced dosage, lower toxicity, and equivalent or superior progression free survival (PFS)...
November 2016: Journal of Experimental Therapeutics & Oncology
https://www.readbyqxmd.com/read/27816996/alisertib-demonstrates-significant-antitumor-activity-in-bevacizumab-resistant-patient-derived-orthotopic-models-of-glioblastoma
#4
C Kurokawa, H Geekiyanage, C Allen, I Iankov, M Schroeder, B Carlson, K Bakken, J Sarkaria, J A Ecsedy, A D'Assoro, B Friday, E Galanis
Aurora A kinase (AURKA), a member of the serine/threonine kinase family, plays a critical role in cell division, and it is widely overexpressed in a variety of tumors including glioblastoma (GBM). Alisertib (MLN8237) is an orally administered selective AURKA inhibitor with potent antiproliferative activity, currently undergoing clinical testing in different tumor types. In vitro evaluation of alisertib against the primary GBM lines, GBM6, GBM10, GBM12 and GBM39 showed significant antitumor activity with IC50s ranging between 30 and 95 nM...
November 5, 2016: Journal of Neuro-oncology
https://www.readbyqxmd.com/read/27815391/quantitative-fluorescent-microscopy-to-measure-vascular-pore-sizes-in-primary-and-metastatic-brain-tumors
#5
Rajendar K Mittapalli, Chris E Adkins, Kaci A Bohn, Afroz S Mohammad, Julie A Lockman, Paul R Lockman
Tumors residing in the central nervous system (CNS) compromise the blood-brain barrier (BBB) via increased vascular permeability, with the magnitude of changes dependent on tumor type and location. Current studies determine penetrability of a cancer therapeutic by administering progressively larger molecules until cutoff is observed where little to no tumor accumulation occurs. However, decades-old experimental work and mathematical modeling document methods to calculate both the size of the vascular opening (pore) with solute permeability values...
November 4, 2016: Cancer Research
https://www.readbyqxmd.com/read/27803607/progression-pattern-and-adverse-events-with-bevacizumab-in-glioblastoma
#6
A Mamo, A Baig, M Azam, Y S Rho, S Sahebjam, T Muanza, S Owen, K Petrecca, M C Guiot, J Al-Shami, R Sharma, P Kavan
BACKGROUND: The use of bevacizumab in the management of glioblastoma multiforme (gbm) remains controversial. In Canada, bevacizumab is approved for the treatment of recurrent gbm. We describe a pattern of progression across treatment lines in gbm. METHODS: During 2008-2014, 64 patients diagnosed with gbm were treated with bevacizumab at McGill University hospitals. Of those patients, 30 (46.9%) received bevacizumab in the first line (B1L), and 34 (53.1%) received it in the second line and beyond (B2L+)...
October 2016: Current Oncology
https://www.readbyqxmd.com/read/27803067/large-scale-radiomic-profiling-of-recurrent-glioblastoma-identifies-an-imaging-predictor-for-stratifying-anti-angiogenic-treatment-response
#7
Philipp Kickingereder, Michael Götz, John Muschelli, Antje Wick, Ulf Neuberger, Russell T Shinohara, Martin Sill, Martha Nowosielski, Heinz-Peter Schlemmer, Alexander Radbruch, Wolfgang Wick, Martin Bendszus, Klaus H Maier-Hein, David Bonekamp
PURPOSE: Antiangiogenic treatment with bevacizumab, a mAb to the VEGF, is the single most widely used therapeutic agent for patients with recurrent glioblastoma. A major challenge is that there are currently no validated biomarkers that can predict treatment outcome. Here we analyze the potential of radiomics, an emerging field of research that aims to utilize the full potential of medical imaging. EXPERIMENTAL DESIGN: A total of 4,842 quantitative MRI features were automatically extracted and analyzed from the multiparametric tumor of 172 patients (allocated to a discovery and validation set with a 2:1 ratio) with recurrent glioblastoma prior to bevacizumab treatment...
December 1, 2016: Clinical Cancer Research: An Official Journal of the American Association for Cancer Research
https://www.readbyqxmd.com/read/27777151/management-of-patients-with-primary-intramedullary-spinal-cord-glioblastoma
#8
Bedjan Behmanesh, Matthias Setzer, Juergen Konczalla, Patrick Harter, Johanna Quick-Weller, Lioba Imoehl, Kea Franz, Florian Gessler, Volker Seifert, Gerhard Marquardt
BACKGROUND: Primary intramedullary spinal cord glioblastoma are very rare tumors of the spinal cord. They imply a very poor prognosis since complete surgical resection is not possible due to the infiltrative growth of these tumors. The aim of this study is to present our data achieved with an aggressive multimodality treatment. METHODS: We retrospectively reviewed our clinical database. All patients with histologically proven intramedullary spinal cord glioblastoma treated in our department were included in this study...
October 21, 2016: World Neurosurgery
https://www.readbyqxmd.com/read/27770279/nrg-oncology-rtog-0625-a-randomized-phase-ii-trial-of-bevacizumab-with-either-irinotecan-or-dose-dense-temozolomide-in-recurrent-glioblastoma
#9
Mark R Gilbert, Stephanie L Pugh, Ken Aldape, A Gregory Sorensen, Tom Mikkelsen, Marta Penas-Prado, Felix Bokstein, Young Kwok, R Jeffrey Lee, Minesh Mehta
Angiogenesis, a hallmark of glioblastoma, can potentially be targeted by inhibiting the VEGF pathway using bevacizumab, a humanized monoclonal antibody against VEGF-A. This study was designed to determine the efficacy and safety of these regimens in the cooperative group setting. Eligibility included age ≥18, recurrent or progressive GBM after standard chemoradiation. Treatment was intravenous bevacizumab 10 mg/kg and either irinotecan (CPT) 125 mg/m(2) every 2 weeks or temozolomide (TMZ) 75-100 mg/m(2) day 1-21 of 28 day cycle...
October 21, 2016: Journal of Neuro-oncology
https://www.readbyqxmd.com/read/27758718/current-and-future-drug-treatments-for-glioblastomas
#10
Shigeo Ohba, Yuichi Hirose
Glioblastomas are the most aggressive of all gliomas and have the worst prognosis, with 5-year survival rates of less than 10%. Temozolomide (TMZ) is a DNA-methylating agent. Now that TMZ is available, the standard treatment is to resect as much of the tumor as possible without inducing unacceptable neurologic deficits, followed by treatment with radiation and TMZ. TMZ has also been used for maintenance therapy. Recently, bevacizumab, which is a monoclonal antibody to vascular endothelial growth factor, has been used for the initial treatment of glioblastomas and for the treatment of recurrent glioblastomas...
October 14, 2016: Current Medicinal Chemistry
https://www.readbyqxmd.com/read/27716027/identification-of-gene-drug-interactions-that-impact-patient-survival-in-tcga
#11
John Christian Givhan Spainhour, Peng Qiu
BACKGROUND: With the advent of large scale biological data collection for various diseases, data analysis pipelines and workflows need to be established to build frameworks for integrative analysis. Here the authors present a pipeline for identifying disease specific gene-drug interactions using CNV (Copy Number Variation) and clinical data from the TCGA (The Cancer Genome Atlas) project. Two cancer types were selected for analysis, LGG (Brain lower grade glioma) and GBM (Glioblastoma multiforme), due to the possible progression from LGG to GBM in some cases...
October 6, 2016: BMC Bioinformatics
https://www.readbyqxmd.com/read/27703677/significant-antitumor-response-of-disseminated-glioblastoma-to-bevacizumab-resulting-in-long-term-clinical-remission-in-a-patient-with-encephalocraniocutaneous-lipomatosis-a-case-report
#12
Raita Fukaya, Masatoki Ozaki, Dai Kamamoto, Yukina Tokuda, Tokuhiro Kimura, Masahito Fukuchi, Koji Fujii
The prognosis of recurrent and disseminated glioblastoma is very poor. Bevacizumab is an effective established therapy for recurrent glioblastoma following treatment with radiotherapy plus temozolomide. However, the efficacy of bevacizumab is limited to prolonging progression-free survival, without significant prolongation of the overall survival. We herein report a case of glioblastoma in a 32-year-old female patient with encephalocraniocutaneous lipomatosis (ECCL) that had disseminated following surgical resection and subsequent treatment with temozolomide and radiation therapy...
October 2016: Molecular and Clinical Oncology
https://www.readbyqxmd.com/read/27698790/glioblastoma-multiforme-effect-of-hypoxia-and-hypoxia-inducible-factors-on-therapeutic-approaches
#13
Wen-Juan Huang, Wei-Wei Chen, Xia Zhang
Central nervous system-based cancers have a much higher mortality rate with the 2016 estimates at 6.4 for incidence and 4.3 for deaths per 100,000 individuals. Grade IV astrocytomas, known as glioblastomas are highly aggressive and show a high proliferation index, diffused infiltration, angiogenesis, microvascular proliferation and pleomorphic vessels, resistance to apoptosis, and pseudopalisading necrosis. Extensive hypoxic regions in glioblastomas contribute to the highly malignant phenotype of these tumors...
October 2016: Oncology Letters
https://www.readbyqxmd.com/read/27693246/permeability-surface-area-product-using-perfusion-ct-is-a-valuable-prognostic-factor-in-glioblastomas-treated-with-radiotherapy-plus-concomitant-and-adjuvant-temozolomide
#14
Taiichi Saito, Kazuhiko Sugiyama, Fusao Ikawa, Fumiyuki Yamasaki, Minoru Ishifuro, Takeshi Takayasu, Ryo Nosaka, Yoshihiro Muragaki, Takakazu Kawamata, Kaoru Kurisu
OBJECTIVE: The current standard treatment protocol for patients with newly diagnosed glioblastoma (GBM) includes surgery, radiotherapy, and concomitant and adjuvant temozolomide (TMZ). We hypothesized that the permeability surface area product (PS) from a perfusion CT (PCT) study is associated with sensitivity to TMZ. The aim of this study was to determine whether PS values were correlated with prognosis of GBM patients who received the standard treatment protocol. METHODS: This study included 36 patients with GBM that were newly diagnosed between October 2005 and September 2014 and who underwent preoperative PCT study and the standard treatment protocol...
September 27, 2016: World Neurosurgery
https://www.readbyqxmd.com/read/27684457/effect-of-bevacizumab-plus-temozolomide-radiotherapy-for-newly-diagnosed-glioblastoma-with-different-mgmt-methylation-status-a-meta-analysis-of-clinical-trials
#15
Chigang Du, Junquan Ren, Rui Zhang, Tao Xin, Zhongmin Li, Zhiti Zhang, Xinghua Xu, Qi Pang
BACKGROUND MGMT methylation status can influence the therapeutic effect and prognosis of glioblastoma (GBM). There are conflicting results from studies evaluating the efficacy of bevacizumab (BV) when it is combined with temozolomide (TMZ) and radiotherapy (RT) in patients diagnosed with GBM with different MGMT methylation status. MATERIAL AND METHODS Data were extracted from publications in PubMed, Embase, and The Cochrane Library, with the last search performed March 23, 2016. Data on overall survival (OS), progression-free survival (PFS), and MGMT methylation status were obtained...
2016: Medical Science Monitor: International Medical Journal of Experimental and Clinical Research
https://www.readbyqxmd.com/read/27680966/second-line-treatment-of-recurrent-glioblastoma-with-sunitinib-results-of-a-phase-ii-study-and-systematic-review-of-literature
#16
Salvatore Grisanti, Vittorio D Ferrari, Michela Buglione, Giorgio M Agazzi, Roberto Liserre, Luigi Poliani, Luciano Buttolo, Stefano Gipponi, Rebecca Pedersini, Francesca Consoli, Pierpaolo Panciani, Elisa Roca, Giannantonio Spena, Luca Triggiani, Alfredo Berruti
INTRODUCTION: Second line treatment of recurrent or progressive glioblastoma multiforme (GBM) is not standardized. Anti-angiogenic strategies with tyrosine-kinase inhibitors have been tested with conflicting results. We tested the association of sunitinib (S) plus irinotecan (CPT-11) in a phase II trial in terms of response rate (RR) and 6-months progression-free survival (6-PFS). We also reviewed the clinical evidence from all the trials with S in this setting published to date and summarized it in a meta-analysis...
September 28, 2016: Journal of Neurosurgical Sciences
https://www.readbyqxmd.com/read/27648703/mri-and-11c-methyl-l-methionine-pet-differentiate-bevacizumab-true-responders-after-initiating-therapy-for-recurrent-glioblastoma
#17
Takaaki Beppu, Kazunori Terasaki, Toshiaki Sasaki, Yuichi Sato, Makiko Tomabechi, Kenichi Kato, Makoto Sasaki, Kuniaki Ogasawara
PURPOSE: Normalization of tumor vasculature after administering bevacizumab (BEV) makes assessment of therapeutic response using MRI difficult. The aim of this study was to clarify whether PET with C-methyl-L-methionine (MET-PET) would supplement MRI assessing of response after initiating BEV in glioblastoma. METHODS: Twenty patients with recurrent glioblastoma were treated with biweekly BEV plus temozolomide. Both MRI and MET-PET were performed before treatment (baseline) and at 4 and 8 weeks after starting treatment...
November 2016: Clinical Nuclear Medicine
https://www.readbyqxmd.com/read/27626306/assessment-of-bevacizumab-resistance-increased-by-expression-of-bcat1-in-idh1-wild-type-glioblastoma-application-of-dsc-perfusion-mr-imaging
#18
Hye Rim Cho, Bora Hong, Hyeonjin Kim, Chul-Kee Park, Sung-Hye Park, Sunghyouk Park, Seung Hong Choi
BCAT1 (branched-chain amino acid trasaminase1) expression is necessary for the progression of IDH1 wild-type (WT) glioblastoma multiforme (GBM), which is known to be associated with aggressive tumors. The purpose of our study is to investigate the bevacizumab resistance increased by the expression of BCAT1 in IDH1 WT GBM in a rat model, which was evaluated using DSC perfusion MRI. BCAT1 sh#1 inhibits cell proliferation and limits cell migration potential in vitro. In vivo MRI showed that the increase in both tumor volume and nCBV after bevacizumab treatment in IDH1 WT tumors was significantly higher compared with BCAT1 sh#1tumors...
September 8, 2016: Oncotarget
https://www.readbyqxmd.com/read/27603407/prognostic-value-of-relative-cerebral-blood-volume-rcbv-in-patients-with-recurrent-glioblastoma-multiforme-treated-with-bevacizumab
#19
Alessandro Stecco, Paola Amatuzzo, Andrea P Spongini, Francesca Platini, Martina Quagliozzi, Francesco Buemi, Elena Guenzi, Alessandro Carriero
BACKGROUND: To assess whether the early monitoring of the effects of bevacizumab in patients with recurrent glioblastoma multiforme (GBM) using perfusional dynamic susceptibility contrast (DSC) magnetic resonance imaging (MRI) before and after the beginning of anti-angiogenic therapy is predictive of treatment response. METHODS: Thirteen patients with recurrent GBM underwent perfusion MRI with relative cerebral blood volume (rCBV) mapping before (T0) and after the beginning (T1) of bevacizumab treatment...
September 7, 2016: Journal of Neurosurgical Sciences
https://www.readbyqxmd.com/read/27588142/cost-effectiveness-analysis-of-the-bevacizumab-irinotecan-regimen-in-the-treatment-of-primary-glioblastoma-multiforme-recurrences
#20
Daniel Ruiz-Sánchez, Irene Iglesias Peinado, Miguel Alaguero-Calero, Alejandro José Sastre-Heres, Benito García Diez, Jaime Peña-Díaz
The purpose of the present study was to calculate the cost-effectiveness of the inclusion of the bevacizumab (BVZ) + irinotecan (CPT-11) regimen in the second-line of treatment for primary glioblastoma multiforme. A retrospective cohort study with a control group was performed in which the cost-effectiveness of a course of chemotherapy was calculated based on survival time and the incremental cost between the two lines of treatment. A total of 77 patients were included, 36 of who formed the BVZ/CPT-11 cohort...
September 2016: Oncology Letters
keyword
keyword
80321
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"